The Federal Trade Commission (FTC) filed a lawsuit to stop Memphis, Tennessee-based Methodist Le Bonheur Healthcare’s $250 million acquisition of two hospitals in the area owned by Tenet Healthcare.
The agency said in the federal lawsuit filed Friday that the acquisition of two Memphis-based hospitals known as Saint Francis would imperil competition in the area.
Competition would dampen for a “broad range of inpatient medical and surgical diagnostic and treatment services that require an overnight hospital stay,” the FTC said in a release Friday. “If the proposed acquisition is consummated, healthcare costs will rise.”
FTC said only four hospital systems provide general services to the area. If the deal goes through, the new health system would control approximately 60% of the Memphis market.
“It’s clear that patients in the Memphis area have benefited from the competitive pressure that Saint Francis brings to bear on Methodist, through lower rates, more options for insurers and patients, and quality improvements,” said Daniel Francis, deputy director of the FTC’s Bureau of Competition, in a statement.
FTC is seeking a preliminary injunction to halt the deal until completion of a trial next year.
This is the latest move by the FTC to combat hospital mergers. Last year, the FTC launched a probe into the effects of health system mergers on prices and healthcare quality.
Methodist and Tenet said in a joint statement they are reviewing the lawsuit and were bewildered by the move.
“We are surprised by the FTC action given the strong support for the transaction by local stakeholders, including leading local health plans, physicians, employers and community leaders,” the statement said.
No state in America could clear the threshold right now to safely allow indoor gatherings, Axios’ Sam Baker and Andrew Witherspoon report.
The big picture: This is bad as the pandemic has ever been — the most cases, the most explosive growth and the greatest strain on hospitals.
If businesses were closed right now, it would not be safe to reopen them. And holiday travel will be risky no matter where you’re coming from or where you’re going.
By the numbers: Over the past week, the U.S. averaged more than 154,000 new cases per day, the highest rate of the entire pandemic.
The number of new infections rose in 46 states, held steady in three, and declined in only one — Hawaii.
This week’s nationwide totals are a 30% increase over last week, which was a 40% increase over the week before that. Daily infections have been rising by at least 15% for the past six weeks.
Testing was up about 11% over the past week. The U.S. is now conducting about 1.5 million tests per day. That’s a lot, but cases clearly are still rising faster than testing.
Between the lines:Whatever metric you might use to decide whether it’s safe to have a large Thanksgiving get-together, or to sit inside a bar or restaurant, the answer is probably no.
Experts recently told The Atlantic that they wouldn’t feel comfortable attending an indoor dinner party at all, but that it would be least risky in areas with only about 10–25 new cases per day, per 100,000 people.
The bottom line: Eating and drinking indoors with large groups of people, at a time when 150,000 people are contracting the virus every day, is about as risky as it gets.
The leading coronavirus vaccines are shaping up to be on par with some of the most effective vaccines in medicine, Axios’ Marisa Fernandez reports.
Why it matters:Vaccines with efficacy rates of about 95% — which both Pfizer and Moderna say they’ve achieved — will be more powerful weapons against the coronavirus than many experts had anticipated.
Flashback: The Food and Drug Administration initially set the bar for a COVID-19 vaccine at 50% efficacy, roughly in line with the seasonal flu vaccine.
Some scientists had hoped, in a best-case scenario, it might be as much as 70% effective.
“We don’t know yet what the efficacy might be. We don’t know if it will be 50% or 60%. I’d like it to be 75% or more,” the NIH’s Anthony Fauci said in August.
But coming in closer to 95% would put Pfizer and Moderna’s vaccines more in line with the highly effective inoculations against measles, mumps and rubella.
Like the MMR and polio vaccines, both prospective COVID-19 products would require two shots to reach that level of efficacy.
The third leading contender, being developed by AstraZeneca and Oxford University, would also require two shots. Johnson & Johnson is testing both a single-dose and a two-dose vaccine in simultaneous phase 3 trials.
Yes, but: There’s still a lot we don’t know about these vaccines, including how well they’re likely to work among various demographic groups, and how long the immunity they confer will last.
The disease caused by the novel coronavirus has killed at least 247,000 people in the United States since February and has enveloped nearly every part of the country.
As health officials long predicted, autumn brought soaring case counts, strained hospital capacity and increased deaths nationwide, as the virus is not only popping up in new places but also circling back to areas that once appeared to have it contained. Nearly all metrics in most of the country are trending in the wrong direction.
During an April peak, the seven-day-average U.S. death toll hit more than 2,000 per day, but cases were concentrated largely in the Northeast. During a July lull, average deaths sank to a low of 463 per day, although cases surged in the Sun Belt.
By early November, however, the country was recording more new cases than ever — well over 100,000 per day — and many states reported record-high caseloads and hospitalizations. The average U.S. deaths per day again shot past 1,000, despite improvements in treatment that make survival more likely.
In the past week in the U.S….New daily reported cases rose 26% New daily reported deaths rose 13.5% Covid related hospitalizations rose 23.9%.
Among reported tests, the positivity rate was 10%.
The number of tests reported rose 9.6% from the previous week.
Numbers in this article have fluctuated as testing and reporting criteria have evolved, particularly in areas that were hit early. Three spikes in the deaths chart above reflect large, one-time adjustments: In mid-April, New York City added more than 3,700 deaths. New Jersey added more than 1,800 on June 25. And in September, The Post changed its methodology for reporting deaths in New York and added a one-day increase of more than 2,700 on Sept. 18.
Health officials, including the country’s top infectious disease expert, Anthony S. Fauci, have said the virus has killed more people than official death tolls indicate.
New York, which was slammed with the new disease in spring and where at least 33,000 have died, is one of several states experiencing a second or even third wave.
Sun Belt states had serious outbreaks after Memorial Day when people flocked to beaches. By late summer, parts of the Midwest were inundated. In August and September, clusters appeared in newly reopened college campuses, particularly in the Northeast and Midwest. By October, Upper Midwest, Great Plains and Western states that had previously been mostly spared were reporting major outbreaks, including Minnesota, Wisconsin, Arkansas, the Dakotas and Alaska.
In November, most states reported record-high case counts and greater demand for hospital beds. Several set records for single-day fatalities.
A majority of states and many retail chains required masks in public places by late July, and public health officials touted them as one of the easiest ways to stop the pandemic. Still, some people in even the hardest-hit areas refuse to wear them, despite evidence that they protect wearers and those around them.
People older than 65 and those with obesity and underlying health problems are the mostly likely to die from covid-19, but a large percentage of infections occur in younger, more mobile people. People younger than 40 tend to become less sick but also unknowingly may pass the disease to others around them.
Sparsely populated areas don’t have the huge raw numbers that cities have reported, but some rank among the highest in deaths and cases per capita.
By late October, covid-19 had been documented in all but three U.S. counties and areas in Montana, the Dakotas and Idaho had some of the highest per capita caseloads.
People in very rural areas may be more vulnerable to covid-19 than urbanites, according to a Post analysis of CDC data.
Demand has often overwhelmed testing infrastructure, muddying the ability of officials to get a true picture of the virus’s reach. In June, CDC Director Robert Redfield estimated that, based on antibody tests, the actual number of U.S. residents who had been infected by the virus was likely to be 10 times as high as the number of confirmed cases. More recently, conflicting CDC guidelines about whether people without symptoms should be tested caused confusion and inhibited contact tracing.
A sharp increase in hospitalizations in late October and November demonstrates that the virus is spreading, not just that more testing is finding more asymptomatic cases. A group of Illinois health-care workers predicted in a Nov. 10 open letter to state and Chicago officials that “Illinois will surpass its ICU bed capacity by Thanksgiving.”
Some hospitals, straining to find beds and health-care workers to handle the crush of patients, are considering unusual measures.
In North Dakota, health-care workers who test positive but have no symptoms can continue working in covid-19 wards, according to Gov. Doug Burgum (R). Some facilities in Oklahoma, Kansas and Ohio are limiting routine care and deferring non-emergency surgeries.
Not all news is bleak, however.
On Nov. 9, Pfizer announced that its promising vaccine — one of many in the works — appeared more than 90 percent effective in an ongoing trial. The same day, regulators granted emergency authorization to an antibody treatment that may keep mild illness from becoming severe.
And the next day, Fauci told CNN that the average American may have access to a vaccine by April.
State-level reports are the best publicly available data on child COVID-19 cases in the United States. The American Academy of Pediatrics and the Children’s Hospital Association are collaborating to collect and share all publicly available data from states on child COVID-19 cases (definition of “child” case is based on varying age ranges reported across states; see report Appendix for details and links to all data sources).
As of November 12th, over 1 million children have tested positive for COVID-19 since the onset of the pandemic. The age distribution of reported COVID-19 cases was provided on the health department websites of 49 states, New York City, the District of Columbia, Puerto Rico, and Guam. Children represented 11.5% of all cases in states reporting cases by age.
A smaller subset of states reported on hospitalizations and mortality by age; the available data indicated that COVID-19-associated hospitalization and death is uncommon in children.
The number of new child COVID-19 cases reported this week, nearly 112,000, is by far the highest weekly increase since the pandemic began. At this time, it appears that severe illness due to COVID-19 is rare among children. However, there is an urgent need to collect more data on longer-term impacts on children, including ways the virus may harm the long-term physical health of infected children, as well as its emotional and mental health effects.
Summary of Findings (data available as of 11/12/20) :
(Note: Data represent cumulative counts since states began reporting)
Cumulative Number of Child COVID-19 Cases*
1,039,464 total child COVID-19 cases reported, and children represented 11.5% (1,039,464/9,037,991) of all cases
Overall rate: 1,381 cases per 100,000 children in the population
Change in Child COVID-19 Cases*
111,946 new child COVID-19 cases were reported the past week from 11/5-11/12 (927,518 to 1,039,464)
Over two weeks, 10/29-11/12, there was a 22% increase in child COVID-19 cases (185,829 new cases (853,635 to 1,039,464))
Testing (10 states reported)*
Children made up between 5.0%-17.4% of total state tests, and between 3.9%-18.8% of children tested were tested positive
Hospitalizations (23 states and NYC reported)*
Children were 1.2%-3.3% of total reported hospitalizations, and between 0.5%-6.1% of all child COVID-19 cases resulted in hospitalization
Mortality (42 states and NYC reported)*
Children were 0.00%-0.21% of all COVID-19 deaths, and 16 states reported zero child deaths
In states reporting, 0.00%-0.15% of all child COVID-19 cases resulted in death
* Note: Data represent cumulative counts since states began reporting; All data reported by state/local health departments are preliminary and subject to change
Like a lot of people, I have really gotten into listening to podcasts over the last year. They’re such an immersive way to learn about the world, and I like how the format lets you dive as deep on a topic as you want. So, I was inspired to start one of my own—but I knew I couldn’t do it on my own.
I couldn’t ask for a better partner on this project than Rashida Jones. A mutual friend suggested that the two of us might have a lot to talk about, and it turned out he was right. I already knew she was a talented actor, but I was impressed by her thoughtful perspective on the world. So, we decided to start a podcast that lets us think through some of today’s most pressing problems together. In our first episode, Rashida and I explore a big question that is top of mind for many people: what will the world look like after COVID-19?
I know it’s hard to imagine right now while new cases are surging around the world, but there will come a time when the COVID-19 pandemic is behind us. I think it’s safe to assume that society will be changed forever, given how disruptive the virus has been to virtually every part of our lives.
Unfortunately, we still have a long way to go before life truly gets back to “normal.” Rashida and I were joined by Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, to discuss what to expect in the months to come. I’ve had the opportunity to work with Dr. Fauci on a number of global health issues over the years, including the quest for an HIV vaccine and cure. He’s such a quiet and unassuming guy normally, so it’s been wild to watch him become a huge celebrity.
Dr. Fauci and I are both optimistic that a vaccine will bring an end to the pandemic at some point in the near future. But what the world looks like after that is a lot less clear. I suspect that some of the digitization trends we’ve seen—especially in the areas of online learning, telemedicine, and remote work—will become a regular part of our lives. I hope this episode leaves you hopeful about the future and curious about what comes next.